NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $339.22 -15.64 (-4.41%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$340.38 +1.16 (+0.34%) As of 07/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$338.85▼$360.9850-Day Range$291.75▼$378.1552-Week Range$130.50▼$382.54Volume337,741 shsAverage Volume367,583 shsMarket Capitalization$10.00 billionP/E Ratio45.35Dividend YieldN/APrice Target$360.67Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments. The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts. Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 67% of companies evaluated by MarketBeat, and ranked 408th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Krystal Biotech is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKrystal Biotech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth28.61% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 28.61% in the coming year, from $7.41 to $9.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 45.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 45.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.10.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 8.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.73% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 7.19.Change versus previous monthShort interest in Krystal Biotech has recently increased by 12.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.13 News SentimentKrystal Biotech has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows9 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,243,923.00 in company stock.Percentage Held by Insiders13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesKrystal Biotech (NASDAQ:KRYS) EVP Sells 1,000 SharesJune 27, 2026 | insidertrades.comKrystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)June 25, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue StreamJune 24, 2026 | insidermonkey.comThe Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue StreamJune 24, 2026 | finance.yahoo.com3 Biotech Firms With Major Potential Catalysts in the Coming Months (KRYS)The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.June 22, 2026 | marketbeat.comIs Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comH.C. Wainwright Sticks to Their Buy Rating for Krystal Biotech (KRYS)June 2, 2026 | theglobeandmail.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $246.54 on January 1st, 2026. Since then, KRYS stock has increased by 37.6% and is now trading at $339.22. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) issued its quarterly earnings results on Monday, May, 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm earned $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a trailing twelve-month return on equity of 19.25% and a net margin of 53.92%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $40 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,960,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional shareholders include Handelsbanken Fonder AB (0.31%), GAMMA Investing LLC, Hennion & Walsh Asset Management Inc. and Harbor Investment Advisory LLC. Insiders that own company stock include Suma Krishnan, Dino A Rossi, Daniel Janney, Kathryn Romano, John Charles Thomas and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/04/2026Today7/20/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KRYS's financial health is in the Green zone, according to TradeSmith. KRYS has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$360.67 High Price Target$474.00 Low Price Target$284.00 Potential Upside/Downside+6.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$7.48 Trailing P/E Ratio45.35 Forward P/E Ratio45.78 P/E GrowthN/ANet Income$204.83 million Net Margins53.92% Pretax Margin49.68% Return on Equity19.25% Return on Assets17.62% Debt Debt-to-Equity RatioN/A Current Ratio9.46 Quick Ratio9.06 Sales & Book Value Annual Sales$389.13 million Price / Sales25.70 Cash Flow$6.97 per share Price / Cash Flow48.68 Book Value$42.06 per share Price / Book8.07Miscellaneous Outstanding Shares29,480,000Free Float25,618,000Market Cap$10.00 billion OptionableOptionable Beta0.50 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:KRYS) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
